About Exactmer
Exactmer, incorporated in 2018, is a spin-out company from Imperial College London. Our mission is to redefine what is possible in exact polymer synthesis and set a new industry standard for the manufacturing of polymers bound for use in new medicines.
There is increasing interest in using biopolymers such as oligonucleotides to develop new therapies for a wide range of currently untreatable diseases. These polymers are mostly prepared by solid-state synthesis, resulting in very poor scaling capabilities, low final purity and high prices. This means that the promising development of new therapies is currently limited by the high cost of manufacture - we believe Exactmer can help to solve this problem.
Exactmer specialises in the synthesis of biopolymers (oligonucleotides, peptides) and synthetic polymers (eg PEGs) using our patented Nanostar Sieving Technology, which allows the synthesis of the polymers in liquid phase. We produce polymers of unprecedented precision and length by using this completely new approach, opening the way to supremely accurate polymers for use as pharmaceuticals, and drastically reducing drug manufacturing costs.
- Founding: 2018
- Focus : Service
- Industry : Chemistry
Product portfolio of Exactmer
Here you will find Exactmer
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
